- \n
- History of Cancer Treatment: From Death Sentence to Hope<\/a><\/li>\n
- Innovations in Oncology: Key Achievements in Medicine<\/a><\/li>\n
- Survival Statistics: New Data and Forecasts<\/a><\/li>\n
- The Importance of Early Diagnosis in Cancer Treatment<\/a><\/li>\n
- Modern Therapies and Their Impact on Patients<\/a><\/li>\n
- Summary: Medicine vs. Cancer \u2013 Paths to the Future<\/a><\/li>\n<\/ul>\n
History of Cancer Treatment: From Death Sentence to Hope<\/h2>\n
Only a few decades ago, a diagnosis of \u201ccancer\u201d was almost automatically considered a death sentence, and doctors had only a limited set of tools that more often alleviated symptoms<\/a> than actually influenced the course of the disease. The earliest mentions of cancerous tumors appear in ancient sources \u2013 descriptions of changes resembling cancer can be found in Egyptian papyri, and in the works of Hippocrates and Galen, who interpreted the disease through the then theory of humors, believing its cause to be an \u201cexcess of black bile.\u201d Treatment was mainly limited to surgical procedures performed without anesthesia, primitive cauterizations, and the application of herbs and mixtures whose mechanisms were not understood. The risk of death from bleeding, infection, or pain was similar to that associated with the cancer itself, which is why sufferers often hid symptoms for years, only seeing a doctor at a very advanced stage. A breakthrough came in the 19th century with the development of pathological anatomy and microscopy\u2014German pathologist Rudolf Virchow described cancer as a disease of the cells rather than a \u201cdisorder of body fluids,\u201d opening the way to more scientific understanding of cancers. At the same time, the introduction of anesthesia (ether, chloroform) and antiseptics (Lister) made it possible to perform more radical operations with increasing survival rates. Surgeons started experimenting with extensive procedures\u2014like Halsted’s radical mastectomy for breast cancer\u2014believing that the more tissue was removed, the greater the chance of cure. Despite the brutality of these methods, it was thanks to them that the first documented cases of long-term remissions appeared, slowly changing the narrative around cancer from hopeless to \u201csometimes curable.\u201d Another revolution came with the discovery of X-rays by Wilhelm Roentgen in 1895 and radioactivity by the Curies. It was quickly realized that radiation could destroy cancer cells, and while early attempts at radiotherapy faced serious complications, they proved cancer was not completely resistant to intervention. In the first half of the 20th century, radiation became a basic tool for treating solid tumors\u2014of the head and neck, cervix, and skin. At the same time, the first reports about cytotoxic drugs appeared\u2014the pioneering use of mustard gas in lymphoma patients in the 1940s started the era of chemotherapy. In the 1960s and 1970s, multi-drug chemotherapy regimens were introduced, drastically improving prognosis in certain cancers\u2014especially in children with acute lymphoblastic leukemia, as well as in Hodgkin’s lymphoma and testicular cancer. It was then that the first spectacular successes emerged: from diseases that were almost always fatal to those that became largely curable, with long-term survival rates reaching several dozen percent. Simultaneously, the development of epidemiology and medical statistics enabled systematic monitoring of treatment results, highlighting the crucial role of early cancer detection\u2014the earlier diagnosed, the more effective the available therapies. The first screening programs were implemented, initially for cervical cancer (cytology), and later breast cancer (mammography), gradually reducing mortality in selected cancer groups.<\/p>\n
The advent of molecular biology and cancer genetics in the second half of the 20th century revolutionized our understanding of cancer\u2014from a uniform, \u201cmysterious\u201d disease, it became a complex array of thousands of different disorders with diverse molecular profiles and responses to treatment. The discovery of oncogenes and tumor suppressor genes, mutations in TP53, BRCA1\/2, and the role of genomic instability allowed the development of therapies targeting the specific mechanisms driving a given tumor. In the 1990s and early 21st century, drugs based on molecular mechanisms entered clinical practice\u2014tyrosine kinase receptor inhibitors, monoclonal antibodies, and targeted hormonal therapies. For example, the introduction of imatinib in chronic myeloid leukemia transformed it from a highly deadly disease into a chronic condition, with long-term survival comparable to that of the general population. A similar breakthrough was observed in HER2-positive breast cancer after the introduction of trastuzumab, which significantly reduced the risk of recurrence and death. At the turn of the first and second decades of the 21st century, perhaps the most spectacular stage came\u2014the development of next-generation immunotherapies, particularly immune checkpoint inhibitors (like CTLA-4, PD-1, PD-L1). Thanks to these, lasting responses in melanoma, lung cancer, and some lymphomas began to be observed, even in patients with advanced disease. Parallel strategies evolved, such as CAR-T therapies for selected hematological malignancies, utilizing the patient\u2019s own reprogrammed T lymphocytes to directly attack cancer cells. From the patient and social perspective, the most important change is that cancer in many cases is no longer a clear-cut sentence; it has become a disease that can be lived with for years, often in good overall condition, and in some cases\u2014even cured completely. Five-year survival statistics are systematically rising in most cancer types, and more and more people return to work and normal life after therapy. Today\u2019s approach to cancer involves not just ever more effective drugs but also the development of personalized medicine, value-based healthcare, and supportive and psycho-oncological care. Thus, the history of cancer treatment is a journey from an era when doctors could only accompany patients in suffering to a time when medicine offers real hope\u2014both numerical, in terms of survival statistics, and human, in terms of quality of life and the ability to plan for the future despite a cancer diagnosis.<\/p>\n
Innovations in Oncology: Key Achievements in Medicine<\/h2>\n
Contemporary oncology is developing at an unprecedented pace, and the speed of these changes is most apparent when we look at the evolution of treatment methods over the past two to three decades. The most significant innovation has been personalized medicine, moving away from the \u201cone-size-fits-all\u201d principle to in-depth genetic profiling of tumors. Through cancer genome analyzes, doctors can identify specific mutations (e.g., EGFR, ALK in lung cancer, HER2 in breast cancer) and select drugs targeting<\/a> these molecular \u201cengines\u201d driving the disease. Targeted therapies can block receptors, signaling pathways, or enzymes that are crucial for cancer cell growth, generally sparing healthy tissue. In practice, this means not only greater effectiveness but usually less toxicity compared to classical chemotherapy. The development of biomarker tests\u2014such as HER2, PD-L1, or BRCA1\/2 mutations\u2014today makes it possible to predict treatment response and avoid unnecessary exposure to ineffective therapies. Broader use of NGS panels (next-generation sequencing) allows hundreds of genes to be analyzed simultaneously, qualifying patients for specific therapies or clinical trials\u2014the so-called basket trials\u2014where groups are defined not by tumor location but by mutation type. A huge breakthrough has been brought by immunotherapy<\/a>\u2014methods that \u201cunlock\u201d the patient\u2019s own immune system to better recognize and destroy cancer cells. Immune checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, have revolutionized treatments in melanoma, non-small cell lung cancer, and kidney cancer, among others, leading some patients to years-long remissions and durable responses, which, until recently, seemed unthinkable. In certain groups with advanced melanoma, median survival, once measured in months, can now be measured in years, and a significant proportion of patients remain in long-term remission. Even more advanced immunotherapies include cellular therapies such as CAR-T, involving genetic modification of the patient\u2019s own T lymphocytes to recognize specific antigens on the surface of cancer cells. This method is primarily used in resistant leukemia and lymphomas, opening a new chapter in the treatment of hematological malignancies and giving hope to those who have exhausted all previous therapeutic options. Alongside immunotherapy and targeted therapy, modern radiation therapy plays an essential role. It has moved away from \u201cblind\u201d irradiation of large body areas, and new techniques such as IMRT, VMAT, stereotactic radiotherapy (SBRT, SRS), and proton therapy allow the radiation beam to be sculpted in 3D to spare healthy tissue and deliver high doses to the tumor. Using advanced imaging (IGRT), it is possible to track tumor locations in real-time\u2014crucial, for example, in lung or liver tumors, which move with breathing. Modern oncologic surgery has also undergone deep transformation: minimally invasive laparoscopic and robotic procedures (e.g., Da Vinci systems) permit greater precision, less blood loss, shorter hospital stays, and faster recovery of daily function. Techniques such as SNB (sentinel lymph node biopsy) help limit lymph node removal and reduce complications like lymphoedema in breast cancer surgery. Nuclear medicine and diagnostic imaging\u2014PET-CT, increasingly PET-MRI, advanced MRI and CT\u2014have brought a new quality to treatment planning, response monitoring, and early recurrence detection, enabling faster therapeutic response. Moreover, innovations in oncology include combined and sequential therapies, wisely integrating surgery, radiotherapy, chemotherapy, immunotherapy, and targeted drugs to hit cancer from multiple directions and limit its ability to evade treatment. The importance of patients\u2019 quality of life is also growing: modern supportive medications, precision pain management, psycho-oncological support, and cancer rehabilitation programs are now an integral part of the therapeutic pathway. Supported by advanced data analytics, artificial intelligence in imaging, and more clinical trials than ever, all these achievements contribute to gradually improving outcomes for many cancer types and shifting the disease from inevitably fatal to chronic and controllable.<\/p>\n
Survival Statistics: New Data and Forecasts<\/h2>\n
Contemporary oncology survival statistics reveal the dramatic progress of recent decades and the vastly improved prognosis for cancer patients. In the 1970s, five-year survival rates after malignant tumor diagnosis in many countries hovered around 30\u201340%. Today, in numerous cancer types, survival exceeds 60%, and in some cases, even reaches 90%. Registry data such as EUROCARE (Europe), SEER (USA), and national cancer registries clearly show that survival rates are moving upwards. Especially notable is breast cancer, where the combination of screening (mammography), breast-conserving surgery, radiotherapy, hormonal and targeted therapies has pushed five-year survival above 85\u201390% in many developed countries. The same applies to prostate cancer\u2014growing health awareness, PSA testing, and new treatment options have brought five-year survival above 90%. Similarly, in colorectal cancer\u2014once one of the main oncological killers\u2014there is a clear improvement: detection of polyps via colonoscopy, better surgical preparation, laparoscopic methods, and ever-more effective chemo- and biologic therapies are shortening hospitalizations, reducing complication risk, and prolonging overall survival. Today\u2019s analyses differentiate not only five-year survival but also ten-year and conditional survival, tracking how the risk of death decreases as more time passes since diagnosis. For patients, it is also significant that not only \u201cnaked\u201d survival metrics are rising but also the proportion returning to work, family life, and largely functioning without substantial impairment\u2014reflecting the concept of quality-adjusted survival. However, statistics are always averages, and doctors increasingly emphasize prognosis must be judged individually, factoring in disease stage, biological tumor subtype, age, comorbidities, treatment response, and the availability of novel therapies within a country or region.<\/p>\n
\n![\"Modern](\"https:\/\/najzdrowie.pl\/wp-content\/uploads\/Dawne_i_Wsp__czesne_Podej_cie_do_Raka__Medycyna_w_Akcji-1.webp\")
\n<\/a><\/p>\nNew epidemiological data and prognostic models also demonstrate clear survival differences depending on cancer type and time of diagnosis, directly linked to prevention and screening program development. For cervical cancer, the introduction of HPV vaccinations, cytology, and HPV DNA tests has led to a marked drop in incidence and mortality in many countries; in cases diagnosed early, five-year survival can be over 90%. For lung cancer\u2014long considered one of the deadliest\u2014the situation is steadily improving thanks to reduced smoking, low-dose CT screening, and breakthrough targeted therapies<\/a> and immunotherapies\u2014patients with specific mutations or high PD-L1 expression now have a real chance of long-term survival, something nearly impossible just a few years ago. AI-based statistical models analyzing massive clinical, genomic, and imaging datasets allow for much more precise prediction of disease trajectory\u2014not only population-level but individual. Forecasts for coming decades predict a continued increase in the number of people living with cancer as a chronic condition, of course reflecting aging populations but also improving therapy: more and more patients will live many years after diagnosis, often with periodic relapses but without permanent disability. Data also clearly indicate persistent regional and social differences\u2014people living in countries with lower health expenditure, less access to screening and modern therapies, have significantly lower survival compared to those in high-income nations. In response, global initiatives are emerging to equalize chances through standardized guidelines, reference oncology centers, and expanded patient participation in international clinical trials. Epidemiological forecasts suggest that in coming years, survival rates will continue to rise, especially in cancers with intense molecular and immunotherapy development, and survival will increasingly be measured not only in life length but also its fullness and quality.<\/p>\n
The Importance of Early Diagnosis in Cancer Treatment<\/h2>\n
Early cancer diagnosis is one of the most important factors determining patient prognosis\u2014in practice, it means the difference between aggressive, debilitating treatment and the possibility of using less invasive methods, with a high chance of complete cure. In early stages, the tumor is usually confined to its organ of origin, allowing effective surgery or localized treatments (e.g., radiotherapy) and reducing the risk of spread to other body parts. In cancers such as breast, colorectal, or prostate, five-year survival in early stage can exceed 90%, while in metastatic disease, it drops dramatically, often to just several percent. Early detection also reduces treatment burden: patients can avoid extensive surgery, heavy doses of chemotherapy, and prolonged hospitalizations, directly affecting their ability, return to work, and overall quality of life. There is also a psychological aspect\u2014awareness that the disease was caught at a treatable stage lowers anxiety, facilitates cooperation with the medical team, and increases motivation for adherence. From the healthcare system perspective, early diagnosis is also economically beneficial: the cost of screening and early-stage treatment is many times lower than that of advanced cancers requiring expensive drugs, long rehabilitation, and palliative care. That’s why countries with well-organized screening programs<\/a> see not only lower mortality in target cancers but also reduced financial burden.<\/p>\n
The key element in early diagnosis is organized prevention and screening (screening) programs tailored to age, sex, and individual risk factors. Mammography for women over 50 significantly decreases breast cancer mortality, detecting changes before they are clinically palpable. Colonoscopy and fecal occult blood tests can detect polyps and early-stage colorectal cancers that are removable endoscopically before becoming advanced. For cervical cancer, cytology and HPV testing illustrate how the combo of vaccination and screening can dramatically alter disease patterns\u2014where these programs are implemented, incidence and mortality have dropped dramatically. But early diagnosis isn\u2019t limited only to formal screening; it also requires oncological vigilance by family doctors and patients. Persistent cough in smokers, unexplained weight loss, GI bleeding, or chronic pains may be early cancer signals, needing rapid imaging and laboratory testing. Thanks to modern tech\u2014like low-dose CT for lung cancer in high-risk groups, breast MRI in BRCA mutation carriers, and emerging liquid biopsy tests for circulating tumor DNA\u2014early detection capabilities are continually advancing. At the same time, it is crucial that early diagnosis is matched by proper result interpretation and patient communication: overdiagnosis and finding changes of low malignant potential carry the risk of unnecessary treatment, anxiety, and stigma. Therefore, current approaches emphasize evidence-based medicine, individualized risk assessment, clinical decision-support algorithms, and health education, which helps patients interpret screening rationally and participate actively in the care process. As a result, early diagnosis becomes an ongoing process, combining primary prevention (risk reduction), secondary (screening), and tertiary (post-treatment follow-up) into a cohesive cancer care model.<\/p>\n
Modern Therapies and Their Impact on Patients<\/h2>\n
Modern oncological therapies are increasingly turning cancer from an acute, fatal disease into a chronic condition that can be lived with for many years, with relatively good quality of life. Key roles are played by targeted therapies, immunotherapies, modern radiation, minimally invasive surgery, and innovative forms of chemotherapy, including oral treatment. Targeted therapies, based on the genetic mutation analysis of cancer cells (EGFR, ALK, HER2, BRAF, etc.), strike precisely at the mechanisms driving tumor growth while largely sparing healthy tissue. For patients, this usually means milder side effects than classic chemotherapy, shorter hospital stays, and the possibility of leading a more active professional and family life. Immunotherapy with checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) \u201cunlocks\u201d the immune system, previously blocked by the tumor. In clinical practice, this translates to surprisingly long-lasting remissions in some patients with advanced lung cancer, melanoma, or kidney cancer\u2014once considered intractable. Modern stereotactic radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), or proton therapy offer high-dose, highly focused radiation on tumors, minimizing collateral harm. Patients with brain tumors, head and neck cancers, or prostate cancer report fewer complications such as swallowing disorders, incontinence, or chronic pain. Laparoscopic or robotic surgery (e.g., da Vinci systems) means smaller incisions, less risk, and faster return to activity. In breast, gynecologic, and urologic oncology, organ-sparing surgeries (e.g., breast-conserving, prostatectomy with sphincters and nerve preservation) translate directly to maintaining self-esteem, agency, and intimacy. At the same time, oral treatments\u2014targeted or hormonal\u2014allow patients to take medications at home, with regular checkups. This therapy model requires more responsibility and commitment from the patient but better fits work, family care, and social life. An important change in modern therapy is also the shift toward \u201cshared decision-making,\u201d where patients actively participate in choosing therapies, understand the potential benefits and risks, and the doctor explains genetic test results in plain language\u2014supporting greater disease control and reducing anxiety and helplessness.<\/p>\n
The impact of novel therapies, however, is not just medical (survival, remission rates); it also covers emotional, social, and economic domains. On one side, innovation gives patients the real prospect of many years of life\u2014often enabling the planning of work, travels, or even parenting after therapy. For young patients, fertility preservation before aggressive treatments (sperm banking, egg or embryo freezing) is discussed, reflecting a wider approach to post-cancer quality of life. On the other hand, the complexity of new treatment schemes requires regular checkups, vigilant monitoring for side effects, and rapid intervention for serious complications, such as immune organ inflammations with immunotherapy (e.g., bowel, lung, or thyroid<\/a>) or cardiotoxicity of some targeted drugs. Patients need to adapt to long-term specialist care, often involving not just oncologists but cardiologists, endocrinologists, dieticians, or psycho-oncologists. This calls for multidisciplinarity and improved care coordination, but, as a result, increases safety and treatment comfort. Many centers now offer tailored \u201cpatient pathways\u201d and digital applications for real-time symptom reporting, allowing prompt intervention and often preventing hospitalization. The economic aspect cannot be ignored\u2014expensive innovative drugs strain health systems, but for patients, they can mean fewer hospital days, shorter incapacity for work, and less risk of lasting disability, which, in turn, reduces indirect costs. Yet, where reimbursement is limited, not everyone can access the most advanced therapies, affecting patients\u2019 sense of fairness and security. Patient organizations are becoming ever more important, fighting for access to innovation, providing reliable information, and offering support groups. As a result, patients using innovative treatments are less likely to feel alone after diagnosis, and peer support helps them deal with the chronic nature of treatment, disease variability, and the emotional side of life \u201cbetween remission and relapse risk.\u201d<\/p>\n
Summary: Medicine vs. Cancer \u2013 Paths to the Future<\/h2>\n
The confrontation of medicine and cancer is increasingly based on switching from \u201cone-size-fits-all\u201d to individualized, dynamic treatment strategies, taking into account not just tumor histology but also its molecular signatures, growth speed, tumor microenvironment, and the patient\u2019s life situation. At the intersection of molecular biology, bioinformatics, and clinical care, new whole-genome sequencing programs and gene panels are emerging, detecting driver mutations and previously \u201cinvisible\u201d resistance mechanisms. In practice, this leads to selecting targeted therapies based on the presence of specific genetic changes (e.g., EGFR, ALK, BRAF, HER2), as well as the ability to rapidly modify treatment plans as the tumor stops responding to previous drugs. Another area of intense development is so-called liquid biopsies\u2014detecting circulating tumor DNA (ctDNA) and cancer cells in the blood\u2014enabling real-time monitoring, minimal residual disease detection, and very early relapse detection before conventional imaging can show it. Combined with ever-more precise diagnostics (PET-CT, high-field MRI, functional imaging), this creates the basis for dynamic, \u201creactive\u201d therapy planning rooted in current data and not just the time of diagnosis. Behind the scenes, significant organizational and systemic changes are taking place: multidisciplinary tumor boards, coordinated care programs, and competency centers ensure that therapeutic decisions are made collectively by surgeons, clinical oncologists, radiation therapists, pathologists, geneticists, and psychologists, reducing the risk of random, inconsistent actions. At the heart of this transformation is the patient\u2014no longer a passive recipient but a decision-making partner whose values, plans, and fears should shape the approach. Digital tools are playing a larger and larger role: apps for real-time symptom and side effect reporting, remote consultations, at-home vital measurements, and algorithms analyzing the data for risks (e.g., dehydration, infection, hematological toxicity). Alongside artificial intelligence, which helps interpret radiology, pathology, and genomic data, there is faster anomaly identification, personalized medication dosing, and better identification of patients most likely to benefit from particular therapies while reducing severe complication risks. These technological innovations, however, require suitable ethical and legal frameworks\u2014data privacy, algorithm transparency, avoiding model-embedded bias, and equal access to digital solutions remain open challenges, without which new tools may, paradoxically, deepen inequities in oncology rather than reduce them.<\/p>\n
Directions in the development of medicine in the fight against cancer are increasingly encompassing areas recently considered “adjunct”: primary prevention, prehabilitation and cancer rehabilitation, psychological care, health and environmental policy actions. The influence of lifestyle\u2014smoking, diet, physical activity, occupational exposure, air pollution, and alcohol<\/a>\u2014on cancer risk (lung, colorectal, liver, oral cavity, and breast) is ever better documented, prompting decision-makers to invest not only in costly innovative drugs but also in prevention and education programs. At the same time, immunoprophylaxis is developing, including HPV and HBV vaccinations already changing the epidemiology of cervical and liver cancer, perhaps to be joined by further, possibly personalized, anti-cancer vaccines based on individual tumor neoantigens. Therapy is also incorporating new approaches, such as cell engineering (CAR-T, NK cell therapies), RNA therapies, gut microbiome modulation, and combining immunotherapies with targeted therapies<\/a> and radiotherapy in complex, adaptive regimens. A decisive matter for the future is overcoming access barriers to innovation\u2014differences between high- and low-income countries, and between regions of one country, already result in dramatically different prognosis for the same diagnoses. Regulations on reimbursement, flexible outcome-based payment models (value-based healthcare), international clinical trial and data-sharing programs, and the role of patient organizations in health policy will be decisive in determining whether scientific progress benefits all patients. Oncology is thus advancing toward the chronic disease paradigm\u2014developing \u201ccontrolled cancer\u201d models, where the aim is not just cure at any cost, but disease control with the highest possible quality of life, ability to work, family life, and personal ambitions. This requires expansion of care for cancer survivors<\/a>, monitoring of late treatment complications, help with returning to work, and integration of palliative care into mainstream treatment even at early advanced stages. Future paths in the fight against cancer will therefore run in parallel: from genome sequencing labs and new molecule design, through intelligent clinical data analysis systems, to prevention, education, and social actions that will determine whether science\u2019s increasing capabilities translate into widespread, equitable improvement in cancer outcomes for patients worldwide.<\/p>\n
Summary<\/h2>\n
Modern medicine is changing the face of cancer treatment, transforming it from a sentence into a disease that can be fought. Key innovations and advanced therapies significantly increase patient survival, which is reflected in current statistics. Rapid diagnosis is also important, allowing for earlier treatment and better chances of recovery. As science continues to advance, the future of oncology looks ever brighter, delivering patients and doctors new tools in the fight against this serious disease. Modern therapies and innovative approaches offer real hope for a long and healthy life for cancer patients.<\/p>\n","protected":false},"excerpt":{"rendered":"
Cancer treatment has undergone a revolutionary journey, from ancient death sentences to modern therapies offering real hope. The development of medicine has increased survival and improved the quality of life for patients.<\/p>\n","protected":false},"author":6,"featured_media":18891,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","rank_math_title":"Medicine in action to treat cancer: modern therapies","rank_math_description":"Learn about modern cancer treatments and their impact on patients' lives and chances of survival.","rank_math_focus_keyword":"Medicine in action to treat cancer:","rank_math_canonical_url":"https:\/\/najzdrowie.pl\/en\/istory-modern-cancer-treatment-medicine\/","rank_math_robots":null,"rank_math_schema":"","rank_math_primary_category":null,"footnotes":""},"categories":[1066,1068],"tags":[9803,9664,8242,1666,8930,6368,3369,3373,9658,9347,4251,9657,3553],"class_list":["post-18894","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diseases","category-medicine","tag-aortic-aneurysm-diagnostics","tag-crohns-disease","tag-diagnosis-of-aortic-aneurysm","tag-diagnostics","tag-diagnostyka","tag-diet-for-immunity","tag-disease","tag-genetic-testing","tag-hashimotos-disease","tag-immunity-diet","tag-innovations-in-medicine","tag-lymphoma","tag-melatonin"],"_links":{"self":[{"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/posts\/18894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/comments?post=18894"}],"version-history":[{"count":0,"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/posts\/18894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/media\/18891"}],"wp:attachment":[{"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/media?parent=18894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/categories?post=18894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/najzdrowie.pl\/en\/wp-json\/wp\/v2\/tags?post=18894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
- Innovations in Oncology: Key Achievements in Medicine<\/a><\/li>\n